<p>Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS - 獲取免費報告) 的股價在週五的交易中突破了其 50 日移動平均線，此次上漲是由於其財報超出預期。該股的 50 日移動平均價為 15.52 美元，最高交易價達到 15.80 美元。Corvus Pharmaceuticals 的股票最後交易價為 15.55 美元，成交量為 980,529 股。</p>
<p>獲取 <strong>Corvus Pharmaceuticals</strong> 的提醒：</p>
<ul>
<li>2026 年這三隻快速增長的股票的勢頭剛剛開始</li>
</ul>
<p>該公司報告本季度每股收益為（$0.15），低於市場共識預期的（$0.14），差距為（$0.01）。</p>
<h2>華爾街分析師預測增長</h2>
<p>幾家研究公司最近對 CRVS 進行了評估。華爾街 Zen 在 4 月 25 日的報告中將 Corvus Pharmaceuticals 的評級從 “賣出” 上調至 “持有”。巴克萊在 1 月 20 日的研究報告中將 Corvus Pharmaceuticals 的目標價從 16.00 美元上調至 28.00 美元，並給予該公司 “增持” 評級。Weiss Ratings 在 4 月 29 日的研究報告中將 Corvus Pharmaceuticals 的評級從 “賣出（e+）” 上調至 “賣出（d-）”。Cantor Fitzgerald 在 3 月 13 日的報告中重申了對 Corvus Pharmaceuticals 的 “增持” 評級。最後，HC Wainwright 在 1 月 20 日的研究報告中將 Corvus Pharmaceuticals 的目標價從 11.00 美元上調至 27.00 美元，並給予該公司 “買入” 評級。七位股票研究分析師對該股給予了買入評級，一位分析師對該公司的股票給予了賣出評級。根據 MarketBeat.com 的數據，該股目前的共識評級為 “適度買入”，平均目標價為 33.33 美元。</p>
<p><strong>獲取我們對 Corvus Pharmaceuticals 的最新分析</strong></p>
<h2>機構投資者對 Corvus Pharmaceuticals 的看法</h2>
<p>幾家對沖基金和其他機構投資者最近買入和賣出了 CRVS 的股票。GSA Capital Partners LLP 在第三季度將其在 Corvus Pharmaceuticals 的持股增加了 25.9%。GSA Capital Partners LLP 目前擁有 401,407 股該公司的股票，價值 2,958,000 美元，此前在上個季度購買了額外的 82,675 股。NEOS Investment Management LLC 在第三季度收購了價值約 436,000 美元的 Corvus Pharmaceuticals 新股份。SEB Asset Management AB 在第一季度收購了價值約 3,319,000 美元的 Corvus Pharmaceuticals 新股份。肯塔基州教師退休系統在第一季度購買了價值約 117,000 美元的 Corvus Pharmaceuticals 新股份。最後，SG Americas Securities LLC 在第一季度將其在 Corvus Pharmaceuticals 的持股增加了 76.9%。SG Americas Securities LLC 目前擁有 35,420 股該公司的股票，價值 518,000 美元，此前在上個季度購買了額外的 15,399 股。46.64% 的股票目前由機構投資者持有。</p>
<h2>Corvus Pharmaceuticals 的價格表現</h2>
<p>該公司的市值為 13.1 億美元，市盈率為 -29.90，貝塔值為 0.94。該公司有一個 50 日簡單移動平均價為 15.52 美元，200 日簡單移動平均價為 12.83 美元。</p>
<h2>關於 Corvus Pharmaceuticals</h2>
<p>（獲取免費報告）</p>
<p>Corvus Pharmaceuticals, Inc 是一家臨牀階段的生物製藥公司，專注於下一代免疫腫瘤治療的發現和開發。該公司的研究工作集中在利用先天和適應性免疫系統來對抗腫瘤驅動的免疫抑制。通過針對調節免疫細胞功能的關鍵通路，Corvus 旨在創造新型藥物，這些藥物可以與現有的癌症治療相結合，以改善患者的治療效果。</p>
<p>Corvus 的主要研發候選藥物包括旨在抑制腺苷通路的小分子和抗體療法，這是一種已知的腫瘤免疫逃逸介質。</p>
<h2>特色文章</h2>
<ul>
<li>五隻我們更看好的股票，勝過 Corvus Pharmaceuticals</li>
</ul>
<p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資 1,000 美元在 Corvus Pharmaceuticals 嗎？</h2>
<p>在你考慮投資 Corvus Pharmaceuticals 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師正在悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前立即購買……而 Corvus Pharmaceuticals 並不在名單上。</p>
<p>雖然 Corvus Pharmaceuticals 目前在分析師中獲得了適度買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>查看這五隻股票</p>

Corvus制藥

標普全球醫療股指數 ETF - iShares

醫藥突破 ETF - ALPS

<p>Corvus Pharmaceuticals（納斯達克代碼：CRVS）股價超過其 50 日移動平均線 15.52 美元，目前交易價格為 15.55 美元，此前發佈的財報令人失望，每股收益（EPS）為（0.15 美元），比預期低 0.01 美元。分析師的看法不一，其中七位給予 “買入” 評級，一位給予 “賣出” 評級。巴克萊將其目標價從 16.00 美元上調至 28.00 美元，而 HC Wainwright 則設定了 27.00 美元的新目標。機構投資者持有該股票的 46.64%，其市值為 13.1 億美元，市盈率為-29.90</p>

<p>Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS - Get Free Report)'s stock price crossed above its 50-day moving average during trading on Friday following a better than expected earnings announcement. The stock has a 50-day moving average of $15.52 and traded as high as $15.80. Corvus Pharmaceuticals shares last traded at $15.55, with a volume of 980,529 shares traded.</p>
<div class="lb-trans"><p>Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS - 獲取免費報告) 的股價在週五的交易中突破了其 50 日移動平均線，此次上漲是由於其財報超出預期。該股的 50 日移動平均價為 15.52 美元，最高交易價達到 15.80 美元。Corvus Pharmaceuticals 的股票最後交易價為 15.55 美元，成交量為 980,529 股。</p>
</div><p>Get <strong>Corvus Pharmaceuticals</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>Corvus Pharmaceuticals</strong> 的提醒：</p>
</div><ul>
<li>Momentum Is Just Starting for These 3 Rapid-Growth Stocks in 2026</li>
</ul>
<div class="lb-trans"><ul>
<li>2026 年這三隻快速增長的股票的勢頭剛剛開始</li>
</ul>
</div><p>The company reported ($0.15) EPS for the quarter, missing the consensus estimate of ($0.14) by ($0.01).</p>
<div class="lb-trans"><p>該公司報告本季度每股收益為（$0.15），低於市場共識預期的（$0.14），差距為（$0.01）。</p>
</div><h2>Wall Street Analysts Forecast Growth</h2>
<div class="lb-trans"><h2>華爾街分析師預測增長</h2>
</div><p>Several research firms recently weighed in on CRVS. Wall Street Zen raised shares of Corvus Pharmaceuticals from a &#34;sell&#34; rating to a &#34;hold&#34; rating in a report on Saturday, April 25th. Barclays raised their target price on shares of Corvus Pharmaceuticals from $16.00 to $28.00 and gave the company an &#34;overweight&#34; rating in a research note on Tuesday, January 20th. Weiss Ratings raised shares of Corvus Pharmaceuticals from a &#34;sell (e+)&#34; rating to a &#34;sell (d-)&#34; rating in a research note on Wednesday, April 29th. Cantor Fitzgerald reiterated an &#34;overweight&#34; rating on shares of Corvus Pharmaceuticals in a report on Friday, March 13th. Finally, HC Wainwright raised their price objective on shares of Corvus Pharmaceuticals from $11.00 to $27.00 and gave the company a &#34;buy&#34; rating in a research note on Tuesday, January 20th. Seven equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of &#34;Moderate Buy&#34; and an average price target of $33.33.</p>
<div class="lb-trans"><p>幾家研究公司最近對 CRVS 進行了評估。華爾街 Zen 在 4 月 25 日的報告中將 Corvus Pharmaceuticals 的評級從 “賣出” 上調至 “持有”。巴克萊在 1 月 20 日的研究報告中將 Corvus Pharmaceuticals 的目標價從 16.00 美元上調至 28.00 美元，並給予該公司 “增持” 評級。Weiss Ratings 在 4 月 29 日的研究報告中將 Corvus Pharmaceuticals 的評級從 “賣出（e+）” 上調至 “賣出（d-）”。Cantor Fitzgerald 在 3 月 13 日的報告中重申了對 Corvus Pharmaceuticals 的 “增持” 評級。最後，HC Wainwright 在 1 月 20 日的研究報告中將 Corvus Pharmaceuticals 的目標價從 11.00 美元上調至 27.00 美元，並給予該公司 “買入” 評級。七位股票研究分析師對該股給予了買入評級，一位分析師對該公司的股票給予了賣出評級。根據 MarketBeat.com 的數據，該股目前的共識評級為 “適度買入”，平均目標價為 33.33 美元。</p>
</div><p><strong>Get Our Latest Analysis on Corvus Pharmaceuticals</strong></p>
<div class="lb-trans"><p><strong>獲取我們對 Corvus Pharmaceuticals 的最新分析</strong></p>
</div><h2>Institutional Investors Weigh In On Corvus Pharmaceuticals</h2>
<div class="lb-trans"><h2>機構投資者對 Corvus Pharmaceuticals 的看法</h2>
</div><p>Several hedge funds and other institutional investors have recently bought and sold shares of CRVS. GSA Capital Partners LLP grew its stake in shares of Corvus Pharmaceuticals by 25.9% in the 3rd quarter. GSA Capital Partners LLP now owns 401,407 shares of the company's stock worth $2,958,000 after purchasing an additional 82,675 shares during the last quarter. NEOS Investment Management LLC acquired a new stake in Corvus Pharmaceuticals during the third quarter valued at approximately $436,000. SEB Asset Management AB acquired a new stake in Corvus Pharmaceuticals during the first quarter valued at approximately $3,319,000. Teachers Retirement System of The State of Kentucky bought a new stake in Corvus Pharmaceuticals during the first quarter worth approximately $117,000. Finally, SG Americas Securities LLC grew its position in Corvus Pharmaceuticals by 76.9% in the first quarter. SG Americas Securities LLC now owns 35,420 shares of the company's stock worth $518,000 after buying an additional 15,399 shares during the last quarter. 46.64% of the stock is currently owned by institutional investors.</p>
<div class="lb-trans"><p>幾家對沖基金和其他機構投資者最近買入和賣出了 CRVS 的股票。GSA Capital Partners LLP 在第三季度將其在 Corvus Pharmaceuticals 的持股增加了 25.9%。GSA Capital Partners LLP 目前擁有 401,407 股該公司的股票，價值 2,958,000 美元，此前在上個季度購買了額外的 82,675 股。NEOS Investment Management LLC 在第三季度收購了價值約 436,000 美元的 Corvus Pharmaceuticals 新股份。SEB Asset Management AB 在第一季度收購了價值約 3,319,000 美元的 Corvus Pharmaceuticals 新股份。肯塔基州教師退休系統在第一季度購買了價值約 117,000 美元的 Corvus Pharmaceuticals 新股份。最後，SG Americas Securities LLC 在第一季度將其在 Corvus Pharmaceuticals 的持股增加了 76.9%。SG Americas Securities LLC 目前擁有 35,420 股該公司的股票，價值 518,000 美元，此前在上個季度購買了額外的 15,399 股。46.64% 的股票目前由機構投資者持有。</p>
</div><h2>Corvus Pharmaceuticals Price Performance</h2>
<div class="lb-trans"><h2>Corvus Pharmaceuticals 的價格表現</h2>
</div><p>The company has a market cap of $1.31 billion, a P/E ratio of -29.90 and a beta of 0.94. The company has a fifty day simple moving average of $15.52 and a 200-day simple moving average of $12.83.</p>
<div class="lb-trans"><p>該公司的市值為 13.1 億美元，市盈率為 -29.90，貝塔值為 0.94。該公司有一個 50 日簡單移動平均價為 15.52 美元，200 日簡單移動平均價為 12.83 美元。</p>
</div><h2>About Corvus Pharmaceuticals</h2>
<div class="lb-trans"><h2>關於 Corvus Pharmaceuticals</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（獲取免費報告）</p>
</div><p>Corvus Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of next-generation immuno-oncology therapies. The company's research efforts are centered on harnessing both the innate and adaptive immune systems to counteract tumor-driven immunosuppression. By targeting key pathways that regulate immune cell function, Corvus aims to create novel agents that can be combined with existing cancer treatments to improve patient outcomes.</p>
<div class="lb-trans"><p>Corvus Pharmaceuticals, Inc 是一家臨牀階段的生物製藥公司，專注於下一代免疫腫瘤治療的發現和開發。該公司的研究工作集中在利用先天和適應性免疫系統來對抗腫瘤驅動的免疫抑制。通過針對調節免疫細胞功能的關鍵通路，Corvus 旨在創造新型藥物，這些藥物可以與現有的癌症治療相結合，以改善患者的治療效果。</p>
</div><p>Corvus's lead pipeline candidates include small-molecule and antibody therapies designed to inhibit the adenosine pathway, a known mediator of tumor immune escape.</p>
<div class="lb-trans"><p>Corvus 的主要研發候選藥物包括旨在抑制腺苷通路的小分子和抗體療法，這是一種已知的腫瘤免疫逃逸介質。</p>
</div><h2>Featured Articles</h2>
<div class="lb-trans"><h2>特色文章</h2>
</div><ul>
<li>Five stocks we like better than Corvus Pharmaceuticals</li>
</ul>
<div class="lb-trans"><ul>
<li>五隻我們更看好的股票，勝過 Corvus Pharmaceuticals</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Corvus Pharmaceuticals Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1,000 美元在 Corvus Pharmaceuticals 嗎？</h2>
</div><p>Before you consider Corvus Pharmaceuticals, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考慮投資 Corvus Pharmaceuticals 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Corvus Pharmaceuticals wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師正在悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前立即購買……而 Corvus Pharmaceuticals 並不在名單上。</p>
</div><p>While Corvus Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Corvus Pharmaceuticals 目前在分析師中獲得了適度買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看這五隻股票</p>
</div>

Corvus Pharmaceuticals (NASDAQ:CRVS) Share Price Passes Above Fifty Day Moving Average  After Earnings Miss

Market Beat

標普生物技術 3 倍做多 - Direxion

醫療業 ETF - SPDR

標普生物技術 ETF - SPDR

動態生物技術與基因組 ETF - Invesco

2 倍做多納斯達克生物技術 ETF - ProShares

紐交所高增長板生物技術指數 ETF - First Trust

美國制藥 ETF - iShares

生物科技 ETF - VanEck Vectors

醫療業 ETF - Vanguard

Invesco Nasdaq Biotechnology ETF

納斯達克生物科技指數 ETF - iShares Nasdaq

基因改革 ETF - ARK

巴克萊銀行

Corvus 製藥（NASDAQ:CRVS）在收益未達預期後，股價突破了五十日移動平均線